Reducing Gadolinium Exposure in Patients Undergoing Monitoring for Meningiomas
暂无分享,去创建一个
[1] Sohil H. Patel,et al. Intracranial meningioma surveillance using volumetrics from T2‐weighted MRI , 2021, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[2] M. Vargas,et al. Is Contrast Medium Really Needed for Follow-up MRI of Untreated Intracranial Meningiomas? , 2021, American Journal of Neuroradiology.
[3] M. Hayden Gephart,et al. Non-Contrast T2-Weighted MR Sequences for Long Term Monitoring of Asymptomatic Convexity Meningiomas. , 2019, World neurosurgery.
[4] K. Workman,et al. Comparison of ABC/2 estimation and a volumetric computerized method for measurement of meningiomas using magnetic resonance imaging , 2019, Journal of Neuro-Oncology.
[5] A. Bücker,et al. Gadoliniumablagerungen – Morbus Gadolinium , 2019, Der Radiologe.
[6] A. Agildere,et al. Can unenhanced brain magnetic resonance imaging be used in routine follow up of meningiomas to avoid gadolinium deposition in brain? , 2019, Clinical imaging.
[7] W. Moon,et al. Gadolinium Deposition in the Brain: Current Updates , 2018, Korean journal of radiology.
[8] C. James,et al. An overview of meningiomas. , 2018, Future oncology.
[9] Rosewinter Kodzwa. Updates to the ACR Manual on Contrast Media. , 2017, Radiologic technology.
[10] Fernando Calamante,et al. Gadolinium deposition in the brain: summary of evidence and recommendations , 2017, The Lancet Neurology.
[11] Matthew G. Crowson,et al. Cost-effectiveness analysis of a non-contrast screening MRI protocol for vestibular schwannoma in patients with asymmetric sensorineural hearing loss , 2017, Neuroradiology.
[12] M. Weller,et al. EANO guidelines for the diagnosis and treatment of meningiomas. , 2016, The Lancet. Oncology.
[13] Erich P Huang,et al. RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.
[14] Terry K Koo,et al. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. , 2016, Journal Chiropractic Medicine.
[15] Daisuke Takenaka,et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.
[16] P. Brotchie,et al. Magnetic resonance imaging of meningiomas: a pictorial review , 2014, Insights into Imaging.
[17] C. Juan,et al. Calculating the tumor volume of acoustic neuromas: Comparison of ABC/2 formula with planimetry method , 2013, Clinical Neurology and Neurosurgery.
[18] D. Saloner,et al. Modern meningioma imaging techniques , 2010, Journal of Neuro-Oncology.
[19] A. D. Van den Abbeele,et al. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. , 2010, AJR. American journal of roentgenology.
[20] Henrik S. Thomsen,et al. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents , 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.
[21] H. Thomsen. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide , 2006, European Radiology.
[22] Lone Skov,et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.
[23] L. Lin,et al. A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.
[24] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[25] J. Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.